IVN 201

Drug Profile

IVN 201

Alternative Names: Cat-MAT; IVN201

Latest Information Update: 23 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImVisioN GmbH
  • Class Allergens; Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Hypersensitivity

Most Recent Events

  • 19 Mar 2009 ImVisioN completes a phase I trial in Allergy in Switzerland
  • 10 Sep 2008 Phase-I clinical trials in Allergy in Switzerland (Intralymphatic)
  • 07 Mar 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top